Hospital
Indiana University Health Bedford, INC
Indiana University Health Bedford, INC was paid $8.45M by Medicaid between Jan 2018 and Nov 2024, across 91 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoINDIANA UNIVERSITY HEALTH BEDFORD, INC
BEDFORD, IN 47421
BEDFORD, IN 47421
33aNPI1548260284assigned 07/22/2005
33bProvider typeCritical Access Hospital
28Total paid$8.45M
24GClaims226,510
24DCodes billed91
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Indiana
Rank by total paid#3 of 26
Median peer was paid$4.16M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CRAIG, MICHAEL controls 15+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 30,772 | $430K | |
| 2019 | 25,267 | $640K | |
| 2020 | 22,340 | $665K | |
| 2021 | 29,747 | $1.05M | |
| 2022 | 49,859 | $2.15M | |
| 2023 | 44,604 | $2.37M | |
| 2024incomplete | 23,921 | $1.15M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 11,749 | 10,840 | $1.77M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 11,771 | 9,925 | $1.33M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 8,157 | 7,314 | $1.18M |
| 71045 | Radiologic examination, chest; single view | 7.2% | 5,085 | 4,264 | $611K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.5% | 7,476 | 6,204 | $469K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 5.2% | 361 | 301 | $441K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.1% | 7,234 | 6,246 | $343K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.9% | 33,833 | 26,842 | $326K |
| 80053 | Comprehensive metabolic panel | 3.3% | 24,735 | 20,174 | $279K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.1% | 681 | 290 | $176K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.9% | 3,856 | 3,270 | $160K |
| 36415 | Collection of venous blood by venipuncture | 1.7% | 39,699 | 31,938 | $145K |
79 more codes
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.6% | 71 | $135K |
| 80050 | General health panel | 1.4% | 1,362 | $122K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 1,625 | $102K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 274 | $84K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,079 | $79K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,091 | $74K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 740 | $57K |
| 80061 | Lipid panel | <1% | 7,184 | $51K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,762 | $42K |
| 84484 | <1% | 4,125 | $36K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,196 | $35K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,846 | $31K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 684 | $30K |
| 83605 | <1% | 3,544 | $29K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,704 | $27K |
| 87503 | <1% | 1,079 | $27K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,128 | $26K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 678 | $23K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 270 | $20K |
| 81001 | <1% | 3,614 | $18K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 932 | $13K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 439 | $10K |
| 83690 | <1% | 1,509 | $10K | |
| 81003 | <1% | 2,964 | $9K | |
| 83735 | <1% | 1,465 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 218 | $8K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 75 | $7K |
| 83880 | <1% | 553 | $7K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 100 | $7K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 33 | $7K |
| 82607 | <1% | 838 | $7K | |
| 85610 | <1% | 967 | $7K | |
| 85027 | <1% | 1,285 | $6K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 158 | $6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 642 | $6K |
| 84436 | <1% | 1,296 | $6K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 104 | $5K |
| 36591 | <1% | 85 | $5K | |
| 81025 | <1% | 446 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 284 | $2K |
| 87040 | <1% | 543 | $2K | |
| 82043 | <1% | 825 | $2K | |
| 82570 | <1% | 854 | $2K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 133 | $2K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $2K |
| 80076 | <1% | 253 | $2K | |
| 82800 | <1% | 328 | $2K | |
| 87276 | <1% | 203 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 526 | $1K |
| 87275 | <1% | 203 | $1K | |
| 85730 | <1% | 183 | $1K | |
| 85379 | <1% | 154 | $1K | |
| 83721 | <1% | 283 | $893.99 | |
| 73630 | <1% | 15 | $749.75 | |
| 36600 | <1% | 13 | $708.60 | |
| 82728 | <1% | 87 | $705.89 | |
| 82550 | <1% | 154 | $673.47 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17 | $669.30 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 79 | $642.84 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 36 | $621.79 |
| 73562 | <1% | 13 | $614.12 | |
| 87522 | Neg quan hep c or qual rna | <1% | 14 | $589.44 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $500.31 |
| 82803 | <1% | 43 | $467.62 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13 | $385.99 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13 | $385.99 |
| 84153 | <1% | 26 | $340.52 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12 | $308.48 |
| 82140 | <1% | 52 | $261.12 | |
| 82150 | <1% | 16 | $257.88 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $245.11 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 15 | $238.15 |
| 86803 | <1% | 14 | $166.71 | |
| 82948 | <1% | 29 | $140.67 | |
| J2704 | Injection, propofol, 10 mg | 0% | 70 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 53 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 23 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 12 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 80 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCRAIG, MICHAEL (CFO)
| Provider | Location | Paid |
|---|---|---|
| Indiana University Health Southern Indiana Physicians, LLC | Bloomington, IN | $69.64M |
| Indiana University Health Bloomington INC | Bloomington, IN | $28.69M |
| Indiana University Health Arnett INC | Lafayette, IN | $26.01M |
| Southern Indiana Pediatrics, LLC | Bloomington, IN | $10.70M |
| Indiana University Health Paoli INC | Paoli, IN | $4.44M |
| Indiana University Health Bloomington INC | Bloomington, IN | $1.49M |
| Indiana University Health Paoli INC | Paoli, IN | $1.10M |
| Iu Health Bedford Physicians, LLC | Bedford, IN | $1000K |
| Iu Health Morgan Physicians, LLC | Martinsville, IN | $534K |
| Wagoner Family Dentistry, PC | Wagoner, OK | $510K |
| Orthopedics of South Central Indiana LLC | Bloomington, IN | $239K |
| Ambulance Service of Murfreesboro, LLC | Murfreesboro, TN | $16K |
| Indiana University Health Southern Indiana Physicians, LLC | Bloomington, IN | $0.00 |
| Bloomington Endoscopy Center, LLC | Bloomington, IN | $0.00 |
| Indiana University Health Southern Indiana Physicians LLC | Bloomington, IN | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.